Drug Approval | May 25, 2024
Zydus receives final approval from USFDA for Theophylline ER Tablets
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India)
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
Subscribe To Our Newsletter & Stay Updated
